Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
100mg
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Zejula is a prescription medication prescribed for certain types of cancer, specifically ovarian, fallopian tube, and primary peritoneal cancer. It is specifically prescribed for patients with recurrent cancer who have responded to platinum-based chemotherapy.
Zejula belongs to a class of drugs known as PARP (poly ADP-ribose polymerase) inhibitors. These drugs work by blocking the PARP enzyme involved in DNA repair. This inhibition prevents cancer cells from repairing their DNA, leading to cell death and slowing disease progression.
Fact Table | |
---|---|
Formula | C19H20N4O5 |
License | FDA approved |
Bioavailability | High (well absorbed orally) |
Legal status | Prescription only |
Chemical Name | 2-(4-{[3-(4-Morpholinyl)phenyl]carbonyl}piperazin-1-yl)-2H-indazole-7-carboxamide |
Elimination half-life | Approximately 36 hours |
Dosage (Strength) | 100 mg capsules |
Pregnancy | Not recommended; consult a healthcare provider |
Brands | Zejula |
Protein binding | Approximately 83% |
PubChem CID | 24958200 |
MedlinePlus | a617019 |
ChEBI | 134724 |
ATC code | L01XX54 |
DrugBank | DB11793 |
KEGG | D10761 |
Routes of administration | Oral |
The usual dose is 200-300 mg ( 100 mg capsules) once daily. The dosage may be adjusted based on the patient’s weight, platelet count, and overall health.
Zejula may be taken with or without food.
The active ingredient in Zejula is niraparib.
There are no significant drug-drug interactions with Zejula
Zejula has been associated with cases of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), some of which have been fatal. Your doctor should monitor for hematological toxicity and discontinue the medication if MDS/AML is confirmed.
Bone marrow suppression is another significant risk. Your doctor should monitor complete blood counts every week for one month, monthly for the next eleven months, and periodically thereafter to monitor for clinically significant changes.
Changes in blood pressure and heart rate can occur. Patients should have their blood pressure and heart rate monitored at least weekly for the first two months, then monthly for the first year, and periodically after that. Management may include the use of antihypertensive medications and adjustments to the Zejula dose if necessary.
Tell your doctor if you are pregnant or planning to become pregnant.
The most common side effects include:
Zejula [package insert]. Research Park Triangle, NC: GlaxoSmithKline; April 2020.